ProNAi Therapeutics IPO Research Information

ProNAi Therapeutics IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on ProNAi Therapeutics, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
ProNAi Therapeutics	DNAI - NASDAQ	$14.00-$16.00	$17.00	$28.68	8.1 million	7/16/2015
Underwriter(s): Jefferies, BofA Merrill Lynch
Co-Manager(s): Wedbush PacGrow, SunTrust Robinson Humphrey
Industry: Health Care
Filing(s): Filed 2015-06-12 Terms Added 2015-07-06

ProNAi Therapeutics Quote & Chart - Click for current quote - DNAI

About ProNAi Therapeutics (adapted from ProNAi Therapeutics prospectus):
They are a clinical-stage oncology company pioneering a novel class of therapeutics based on our proprietary DNA interference (DNAi) technology platform.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "DNAI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.